Labcyte biopharma partners with AstraZeneca, a big pharma company, to use acoustic dispensing combined with mass spectrometry to greatly advance drug discovery applications.
Labcyte, who developed and commercialized acoustic liquid handling, recently developed techniques for the direct loading of samples into mass spectrometers.
This capability creates the potential for high throughput, low cost, label-free analysis.
AstraZeneca is supporting this development effort with the goal of expanding mass spectrometry-based analysis throughout the entire drug discovery and development process.
The development of an instrument that enables the delivery of test samples into a mass spectrometer through acoustic dispensing will generate better results with lower costs compared to traditional systems, which can be prone to transfer errors and sample contamination.
For further deal information visit Current Agreements (subscription required)
Read: more on AstraZeneca company profile, recent partnering, M&A and financing news and articles
Report: Partnering Deals and Alliances with AstraZeneca
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity